Project Grant R01HL181493
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $688K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06511, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services, awarded Yale University $335,917 on June 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct preclinical investigation of pluripotent stem cell–derived vascular therapeutics. The funded work develops tissue-engineered vascular grafts (TEVGs) seeded with human induced pluripotent stem cell (hiPSC)–derived vascular smooth muscle cells and lined...
- The National Heart, Lung, and Blood Institute awarded Yale University $126,177 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund postdoctoral and early-career research investigating the role of intraflagellar transport protein IFT88 in smooth muscle cell phenotype and vascular remodeling. The research addresses mechanisms by which smooth muscle cells in blood vessel walls transition between differentiated and dedifferentiated phenotypes—a process...
- The National Heart, Lung, and Blood Institute awarded The Research Foundation For The State University of New York $740,447 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer self-healing, tissue-engineered vascular grafts for use as arteriovenous shunts in hemodialysis patients. The award funds development of self-healing tissue-engineered vessels (SH-TEVs) designed to withstand repeated needle cannulation while maintaining mechanical strength and...
- The National Heart, Lung, and Blood Institute awarded Yale University $838,491 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify novel gene variants that drive endothelial cell activation during atherosclerotic cardiovascular disease. The recipient will elucidate mechanisms by which gain-of-function defects in ZFYVE21, an endosome-associated protein highly expressed in endothelial cells, contribute to endothelial cell activation and exacerbate...
- The National Heart, Lung, and Blood Institute awarded Yale University $444,015 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to develop human chimeric antigen receptor natural killer (CAR-NK) cells targeting cardiac fibrosis. The project, funded as an R21 Project Grant, will engineer universal CAR-NK cells derived from hypoimmunogenic human induced pluripotent stem cells with inactivated HLA class I/II and CD47 overexpression to enable off-the-shelf,...
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $169,160 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer hypoimmunogenic induced pluripotent stem cell (iPSC)-derived vascular cells and map immune-vascular interactions that drive immune tolerance and vascular integration. The project addresses clinical barriers to iPSC-based vascular therapies: immune rejection of allogeneic transplants and low differentiation...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded Yale University $577,016 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to support research into the molecular mechanisms underlying endothelial von Willebrand factor exocytosis. The research addresses how von Willebrand factor (VWF), a multifunctional plasma glycoprotein essential to hemostasis and thrombosis, is mobilized from vascular stores in endothelial cells. VWF is synthesized and stored in...
- The National Heart, Lung, and Blood Institute awarded $775,114 to the Research Institute At Nationwide Children's Hospital on June 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct preclinical evaluation of a cell-free tissue-engineered vascular graft designed for congenital heart surgery. The research addresses complications arising from prosthetic biomaterials currently used in surgical repair of complex congenital cardiac anomalies, including thromboembolic...
- The National Heart, Lung, and Blood Institute awarded Yale University $1.68 million under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, to investigate developmental mechanisms driving vascular resiliency in the brain's Circle of Willis. The funded research uses zebrafish and human induced pluripotent stem cell vascular organoids to uncover how loss of the microRNA mir-125a impairs embryonic brain angiogenesis and leads to incomplete Circle of Willis formation with...